Literature DB >> 25126370

Sensitivity of medication use to formulary controls in medicare beneficiaries: a review of the literature.

Rahul Shenolikar1, Amanda Schofield Bruno2, Michael Eaddy3, Christopher Cantrell4.   

Abstract

BACKGROUND: Several studies have examined the impact of formulary management strategies on medication use in the elderly, but little has been done to synthesize the findings to determine whether the results show consistent trends.
OBJECTIVE: To summarize the effects of formulary controls (ie, tiered copays, step edits, prior authorization, and generic substitution) on medication use in the Medicare population to inform future Medicare Part D and other coverage decisions.
METHODS: This systematic review included research articles (found via PubMed, Google Scholar, and specific scientific journals) that evaluated the impact of drug coverage or cost-sharing on medication use in elderly (aged ≥65 years) Medicare beneficiaries. The impact of drug coverage was assessed by comparing patients with some drug coverage to those with no drug coverage or by comparing varying levels of drug coverage (eg, full coverage vs $1000 coverage or capped benefits vs noncapped benefits). Articles that were published before 1995, were not original empirical research, were published in languages other than English, or focused on populations other than Medicare beneficiaries were excluded. All studies selected were classified as positive, negative, or neutral based on the significance of the relationship (P <.05 or as otherwise specified) between the formulary control mechanism and the medication use, and on the direction of that relationship.
RESULTS: Included were a total of 47 research articles (published between 1995 and 2009) that evaluated the impact of drug coverage or cost-sharing on medication use in Medicare beneficiaries. Overall, 24 studies examined the impact of the level of drug coverage on medication use; of these, 96% (N = 23) supported the association between better drug coverage (ie, branded and generic vs generic-only coverage, capped benefit vs noncapped benefit, supplemental drug insurance vs no supplemental drug insurance) or having some drug coverage and enhanced medication use. Furthermore, 84% (N = 16) of the 19 studies that examined the effect of cost-sharing on medication use demonstrated that decreased cost-sharing was significantly associated with improved medication use.
CONCLUSION: Current evidence from the literature suggests that restricting drug coverage or increasing out-of-pocket expenses for Medicare beneficiaries may lead to decreased medication use in the elderly, with all its potential implications.

Entities:  

Year:  2011        PMID: 25126370      PMCID: PMC4106498     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


  62 in total

1.  Growing differences between Medicare beneficiaries with and without drug coverage.

Authors:  J A Poisal; L Murray
Journal:  Health Aff (Millwood)       Date:  2001 Mar-Apr       Impact factor: 6.301

2.  Medicare beneficiaries' management of capped prescription benefits.

Authors:  E R Cox; C Jernigan; S J Coons; J L Draugalis
Journal:  Med Care       Date:  2001-03       Impact factor: 2.983

3.  Impact of health plan design and management on retirees' prescription drug use and spending, 2001.

Authors:  Cindy Parks Thomas; Stanley S Wallack; Sue Lee; Grant A Ritter
Journal:  Health Aff (Millwood)       Date:  2002 Jul-Dec       Impact factor: 6.301

4.  Do seniors get the medicines prescribed for them? Evidence from the 1996-1999 Medicare Current Beneficiary Survey.

Authors:  Benjamin M Craig; David H Kreling; David A Mott
Journal:  Health Aff (Millwood)       Date:  2003 May-Jun       Impact factor: 6.301

5.  Seniors with chronic health conditions and prescription drugs: benefits, wealth, and health.

Authors:  Barry G Saver; Mark P Doescher; J Elizabeth Jackson; Paul Fishman
Journal:  Value Health       Date:  2004 Mar-Apr       Impact factor: 5.725

6.  The impact of drug coverage on COX-2 inhibitor use in Medicare.

Authors:  Jalpa A Doshi; Nicole Brandt; Bruce Stuart
Journal:  Health Aff (Millwood)       Date:  2004 Jan-Jun       Impact factor: 6.301

7.  Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit.

Authors:  Michele M Spence; Rita Hui; James Chan
Journal:  J Manag Care Pharm       Date:  2006-06

8.  Medicare Part D--the sea of choices meets the donut hole.

Authors:  Paul J Flaer; Alain Dondériz; Mustafa Z Younis
Journal:  J Health Care Finance       Date:  2007

9.  Prescription drug coverage, utilization, and spending among Medicare beneficiaries.

Authors:  M Davis; J Poisal; G Chulis; C Zarabozo; B Cooper
Journal:  Health Aff (Millwood)       Date:  1999 Jan-Feb       Impact factor: 6.301

10.  Pharmacy benefits and the use of drugs by the chronically ill.

Authors:  Dana P Goldman; Geoffrey F Joyce; Jose J Escarce; Jennifer E Pace; Matthew D Solomon; Marianne Laouri; Pamela B Landsman; Steven M Teutsch
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

View more
  2 in total

1.  Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.

Authors:  Pengxiang Li; Tianyan Hu; Xinyan Yu; Salim Chahin; Nabila Dahodwala; Marissa Blum; Amy R Pettit; Jalpa A Doshi
Journal:  Health Serv Res       Date:  2017-07-24       Impact factor: 3.402

2.  Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge Medicines (CLEAN Meds) trial.

Authors:  Nav Persaud; Taehoon Lee; Haroon Ahmad; Winny Li; Michael Sergio Taglione; Yathavan Rajakulasingam; Norman Umali; Andrew Boozary; Richard H Glazier; Tara Gomes; Stephen W Hwang; Peter Jüni; Michael Law; Muhammad M Mamdani; Braden Manns; Danielle Martin; Steve Morgan; Paul Oh; Andrew David Pinto; Baiju R Shah; Frank M Sullivan; Kevin E Thorpe; Karen Tu; Andreas Laupacis
Journal:  BMJ Open       Date:  2017-06-12       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.